BR112020013094A2 - Anticorpo monoclonal neutralizante totalmente humano nativo contra toxina tetânica e suas aplicações - Google Patents

Anticorpo monoclonal neutralizante totalmente humano nativo contra toxina tetânica e suas aplicações Download PDF

Info

Publication number
BR112020013094A2
BR112020013094A2 BR112020013094-0A BR112020013094A BR112020013094A2 BR 112020013094 A2 BR112020013094 A2 BR 112020013094A2 BR 112020013094 A BR112020013094 A BR 112020013094A BR 112020013094 A2 BR112020013094 A2 BR 112020013094A2
Authority
BR
Brazil
Prior art keywords
seq
monoclonal antibody
neutralizing monoclonal
amino acid
antigen
Prior art date
Application number
BR112020013094-0A
Other languages
English (en)
Portuguese (pt)
Inventor
Huaxin Liao
Yueming Wang
Xiaohui Yuan
Weihong Zheng
Original Assignee
Zhuhai Trinomab Biotechnology Co., Ltd.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from CN201711482969.7A external-priority patent/CN108218984B/zh
Priority claimed from CN201711486732.6A external-priority patent/CN108314731B/zh
Priority claimed from CN201711486693.XA external-priority patent/CN108314730B/zh
Priority claimed from CN201810420730.5A external-priority patent/CN108623681B/zh
Application filed by Zhuhai Trinomab Biotechnology Co., Ltd. filed Critical Zhuhai Trinomab Biotechnology Co., Ltd.
Publication of BR112020013094A2 publication Critical patent/BR112020013094A2/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/12—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from bacteria
    • C07K16/1267—Gram-positive bacteria
    • C07K16/1282—Clostridium (G)
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/569—Immunoassay; Biospecific binding assay; Materials therefor for microorganisms, e.g. protozoa, bacteria, viruses
    • G01N33/56911—Bacteria
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/577—Immunoassay; Biospecific binding assay; Materials therefor involving monoclonal antibodies binding reaction mechanisms characterised by the use of monoclonal antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/195—Assays involving biological materials from specific organisms or of a specific nature from bacteria
    • G01N2333/33—Assays involving biological materials from specific organisms or of a specific nature from bacteria from Clostridium (G)

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Urology & Nephrology (AREA)
  • Hematology (AREA)
  • Biomedical Technology (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Biochemistry (AREA)
  • Organic Chemistry (AREA)
  • Food Science & Technology (AREA)
  • Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Biotechnology (AREA)
  • Cell Biology (AREA)
  • General Physics & Mathematics (AREA)
  • Microbiology (AREA)
  • Analytical Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Virology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Peptides Or Proteins (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
BR112020013094-0A 2017-12-29 2018-12-28 Anticorpo monoclonal neutralizante totalmente humano nativo contra toxina tetânica e suas aplicações BR112020013094A2 (pt)

Applications Claiming Priority (9)

Application Number Priority Date Filing Date Title
CN201711482969.7A CN108218984B (zh) 2017-12-29 2017-12-29 一种抗破伤风毒素的全人源中和抗体
CN201711486732.6A CN108314731B (zh) 2017-12-29 2017-12-29 一种针对破伤风毒素的全人源单克隆中和抗体及其应用
CN201711486693.X 2017-12-29
CN201711482969.7 2017-12-29
CN201711486732.6 2017-12-29
CN201711486693.XA CN108314730B (zh) 2017-12-29 2017-12-29 抗破伤风毒素中和抗体及其制备与应用
CN201810420730.5 2018-05-04
CN201810420730.5A CN108623681B (zh) 2018-05-04 2018-05-04 一种抗破伤风毒素的中和抗体及应用
PCT/CN2018/124958 WO2019129214A1 (zh) 2017-12-29 2018-12-28 针对破伤风毒素的全人源单克隆中和抗体及其应用

Publications (1)

Publication Number Publication Date
BR112020013094A2 true BR112020013094A2 (pt) 2021-03-30

Family

ID=67063214

Family Applications (1)

Application Number Title Priority Date Filing Date
BR112020013094-0A BR112020013094A2 (pt) 2017-12-29 2018-12-28 Anticorpo monoclonal neutralizante totalmente humano nativo contra toxina tetânica e suas aplicações

Country Status (6)

Country Link
US (1) US11725046B2 (https=)
EP (1) EP3733699A4 (https=)
JP (1) JP7368670B2 (https=)
AU (1) AU2018395100B2 (https=)
BR (1) BR112020013094A2 (https=)
WO (1) WO2019129214A1 (https=)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN118139879A (zh) * 2021-09-07 2024-06-04 生物医学研究院 结合破伤风毒素的抗体及其用途
CN114044819B (zh) * 2021-09-29 2024-07-12 上海儒克生物科技有限公司 全羊源单克隆抗体的高通量制备方法
CN119700969A (zh) * 2023-09-27 2025-03-28 珠海泰诺麦博制药股份有限公司 一种抗破伤风毒素抗体在预防或治疗破伤风中的应用
CN118812707B (zh) * 2024-09-20 2024-12-31 北京科兴中维生物技术有限公司 抗破伤风毒素抗体及应用
CN120829503B (zh) * 2025-09-18 2025-12-26 北京科兴中维生物技术有限公司 抗破伤风毒素抗体及其制备方法与应用

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2627076B2 (ja) * 1988-08-19 1997-07-02 森永製菓株式会社 抗破傷風毒素ヒト型モノクローナル抗体、それを利用した破傷風毒素中和剤及びヒト型モノクローナル抗体産生ハイブリドーマ
US6657103B1 (en) * 1990-01-12 2003-12-02 Abgenix, Inc. Human antibodies derived from immunized xenomice
DK0562132T3 (da) * 1992-03-23 1999-03-22 Schweiz Serum & Impfinst Monoklonale antistoffer mod tetanustoksin og farmaceutiske præparater indeholdende dem
JP2001299360A (ja) 2000-04-28 2001-10-30 Morihiro Matsuda ヒト型抗破傷風毒素一本鎖組換え抗体フラグメント
US20040253242A1 (en) * 2000-12-05 2004-12-16 Bowdish Katherine S. Rationally designed antibodies
CN1305904C (zh) 2003-12-30 2007-03-21 龚小迪 人源的抗破伤风毒素单克隆抗体的制备和应用
CN101220096B (zh) * 2003-12-30 2010-09-29 龚小迪 人源抗破伤风毒素单克隆抗体的制备和应用
CN105153305B (zh) * 2015-06-26 2019-03-01 安泰吉（北京）生物技术有限公司 一种全人源抗破伤风毒素单克隆抗体及其衍生物制备方法和应用
CN108314731B (zh) * 2017-12-29 2019-02-12 珠海泰诺麦博生物技术有限公司 一种针对破伤风毒素的全人源单克隆中和抗体及其应用
CN108314730B (zh) * 2017-12-29 2019-01-08 珠海泰诺麦博生物技术有限公司 抗破伤风毒素中和抗体及其制备与应用
CN108218984B (zh) * 2017-12-29 2018-10-26 珠海泰诺麦博生物技术有限公司 一种抗破伤风毒素的全人源中和抗体
CN108623681B (zh) * 2018-05-04 2019-05-24 珠海泰诺麦博生物技术有限公司 一种抗破伤风毒素的中和抗体及应用

Also Published As

Publication number Publication date
AU2018395100A1 (en) 2020-07-23
EP3733699A1 (en) 2020-11-04
US11725046B2 (en) 2023-08-15
JP7368670B2 (ja) 2023-10-25
AU2018395100B2 (en) 2025-01-23
WO2019129214A1 (zh) 2019-07-04
JP2021508495A (ja) 2021-03-11
EP3733699A4 (en) 2022-06-08
US20210002356A1 (en) 2021-01-07

Similar Documents

Publication Publication Date Title
BR112020013094A2 (pt) Anticorpo monoclonal neutralizante totalmente humano nativo contra toxina tetânica e suas aplicações
JP2020529839A (ja) Ｒｏｒ１及びｃｄ３に対する二重特異性抗体
CN109072212A (zh) 改善的分选酶
CN103459420B (zh) 用于治疗肿瘤的组合物和方法
CN108218984B (zh) 一种抗破伤风毒素的全人源中和抗体
JP2022025094A (ja) 深共融溶媒におけるソルターゼａを利用したアミド基転移
CN107073096A (zh) 结合OprF和OprI的抗体治疗
CN112225813B (zh) 针对破伤风毒素的抗体及其用途
CN109310758A (zh) 针对肠病毒71的人源化抗体
WO2019128121A1 (zh) 抗破伤风毒素中和抗体及其制备与应用
JP2018531009A6 (ja) 深共融溶媒におけるソルターゼａを利用したアミド基転移
US8507655B2 (en) Antibody against anthrax toxins
JP2019508402A (ja) チオールベースの深共融溶媒
CN103998059B (zh) 用于中和狂犬病病毒的结合分子
CN101120018A (zh) 绿脓假单胞菌iats o11血清型脂多糖（lps）特异性人单克隆抗体
JP2018531008A (ja) ソルターゼａを利用してチオエステルを作製するための方法
US20240218055A1 (en) Lassa virus-specific nanobodies and methods of their use
WO2019210552A1 (zh) 一种抗破伤风毒素的中和抗体及应用
AU2008332943B2 (en) G immunoglobulin used against anthrax toxins
CN116925231B (zh) 一种抗mmp19蛋白的抗体及其应用
JP2018531006A (ja) 可溶性ソルターゼａ
JP2018531006A6 (ja) 可溶性ソルターゼａ
HK40109873A (zh) Rsv pre-f截短体及其生产方法和应用
HK40109873B (zh) Rsv pre-f截短体及其生产方法和应用
WO2024155381A1 (en) Antibodies for zika virus

Legal Events

Date Code Title Description
B06W Patent application suspended after preliminary examination (for patents with searches from other patent authorities) chapter 6.23 patent gazette]